Miracor Medical Systems GmbH announced today that its PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) System, designed to improve outcomes for acute coronary syndrome (ACS) and heart failure patients, has been cited as a technology that "may advance heart failure (HF) treatment significantly".
“Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease”
The PICSO® citation appears in a paper, "Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease", published in the current issue of Recent Patents on Biomedical Engineering and authored by Kiyotaka Fukamachi, M.D., Ph.D. Dr. Fukamachi is Section Head, Biomedical Devices, Lerner Research Institute, The Cleveland Clinic Foundation. Dr. Fukamachi also is a Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; and Professor of Biomedical Engineering at Case Western Reserve University.
"There is a dire, unmet clinical need for PICSO® both for ACS and heart failure patients. Nearly 30% of heart attack patients have suboptimal blood flow even after coronary angioplasty, increasing their risk of death within a year by almost three-fold. PICSO® is designed to help these patients," said Jon H. Hoem, Miracor CEO.
ALPK2 identified as promising new therapeutic target for treatment of heart failure